Sleep supports the formation of immunological memory as evidenced by a stronger immune response to vaccination if subjects sleep during the subsequent night than if they stay awake. One mechanism underlying this adjuvant-like action of sleep might be an enhanced homing of circulating naïve T cells to lymph nodes. Indeed, compared to nocturnal wakefulness, sleep acutely lowers T cell counts in peripheral blood during the early night, with the efflux of these cells to lymphoid tissues possibly mediated by sleep-associated release of the mineralocorticoid aldosterone. We show here that blocking mineralocorticoid receptors by spironolactone (200 mg, orally at 23:00 h and again at 4:00 h) in 11 healthy men enhances naïve T-helper cell counts in blood during early nocturnal sleep. Effects in the same direction on naïve cytotoxic T cells and central memory T-helper cells were less consistent. Spironolactone did not influence T cell subsets not migrating to lymph nodes (i.e., CD62L
Introduction
Sleep deeply impacts adaptive immune functions. Specifically, it has been shown that, compared with wakefulness, sleep on the night after vaccination leads to a long lasting enhancement of antigen-specific antibody and T-helper cell responses (Lange et al., 2003 (Lange et al., , 2011 ). An adaptive immune response is initiated by antigen presenting cells and naïve T cells that meet in secondary lymphoid organs, with the number of naïve T cells recruited to lymphoid organs essentially determining the size of the adaptive response, i.e., the number of effector T cells formed after vaccination (Pulendran and Ahmed, 2006) . Therefore, sleep might support the formation of adaptive immunity by increasing migration of T lymphocytes to lymph nodes.
In humans, numbers of T cells in peripheral blood fluctuate along the sleep-wake-cycle, which is due to combined influences of the circadian system and sleep on cell traffic. So, T cell numbers peak during early night and show a strong cortisol-mediated decrease in the morning, which is not dependent on sleep as the rhythm persists at large during 24 h of continuous wakefulness (Born et al., 1997; Dimitrov et al., 2009 ). However, although overall still higher than during daytime, numbers of T cells become reduced in the early night hours when subjects sleep compared to the corresponding period when they remain awake. This shows that early sleep fosters the extravasation of T cells and most likely they are redirected to lymph nodes. Indeed, animal experiments provide hints that sleep leads to an accumulation of lymphocytes in lymph nodes (Dickstein et al., 2000; Zager et al., 2007) . However, the underlying mechanisms are not known. One potential candidate mediating such an influence of sleep on T cell migration is the steroid hormone aldosterone, as this hormone has not only been revealed to enhance the extravasation of lymphocytes in rats (Miller et al., 1994) but is also released in a strongly sleep-dependent fashion with highest pulse amplitudes and plasma levels during sleep (Charloux et al., 1999 (Charloux et al., , 2001 . Aldosterone is produced by the adrenal cortex and acts via the mineralocorticoid receptor (MR) which is also found in lymphocytes (Armanini et al., 1985 (Armanini et al., , 1988 .
To examine the possible contribution of aldosterone to T cell migration, here we tested effects of the MR antagonist spironolactone on numbers of T cells and their subpopulations in peripheral blood of healthy men during nocturnal sleep. We distinguished between CD4 + cell subsets are known to recirculate through lymph nodes whereas CD62L À effector memory and effector T cells do not (von Andrian and Mackay, 2000) . We also monitored CD62L expression to elucidate if aldosterone promotes the extravasation of T cells via increases in this adhesion molecule, which plays an important role for the homing of T cells to lymph nodes (Butcher and Picker, 1996; von Andrian and Mackay, 2000) . Another purpose of the study was to examine if the sleep-independent decrease in peripheral T cell numbers during early morning, which is thought to reflect a redistribution of these cells to the bone marrow following the circadian cortisol rise (Dimitrov et al., 2009) , is mediated exclusively via glucocorticoid receptors (GR). To this end, a second dose of spironolactone was administered at 4:00 h to counteract the effects of the morning rise in cortisol on MR.
Methods

Subjects
Eleven healthy men participated in this study (mean age, 20 years; range 18-27 years). All subjects had a normal nocturnal sleep pattern, did not take any medications at the time of the experiment and were nonsmokers. Acute and chronic illness was excluded by medical history, physical examination, and routine laboratory investigation. The men were synchronized by daily activities and nocturnal rest. They had a regular sleep-wake rhythm for at least 6 weeks before the experiments and no signs of sleep disturbances, including apnea and nocturnal myoclonus. All subjects spent one adaptation night in the laboratory in order to become accustomed to the experimental setting. The study was approved by the Ethics Committee of the University of Lübeck (Lübeck, Germany) and all participants gave written informed consent in accordance with the Declaration of Helsinki.
Experimental design
During this double-blind, randomized study participants spent two experimental nights in the sleep laboratory (in addition to the adaptation night). On these nights, subjects arrived at the laboratory at 21:00 h for preparing blood sampling and polysomnographic recordings. Sleep was allowed between 23:00 h (lights off) and 7:00 h. Subjects received either 200 mg of spironolactone or placebo (orally) right before lights were turned off and a second dosage of spironolactone or placebo, respectively, at approximately 4:00 h. The second dosage was given to assure a high plasma concentration of spironolactone during the second night half and early morning known to be associated with high levels of the endogenous MR ligands aldosterone and cortisol. To this end subjects in both experimental conditions were gently awakened between 3:45 and 4:15 h, as soon as they had entered sleep stage 2. Awakenings from rapid eye movement (REM) sleep or slow wave sleep (SWS) were avoided.
Blood was sampled first at 23:00 h and then every 1.5 h until 9:30 h via an intravenous forearm catheter which was connected to a long thin tube and enabled blood collection from an adjacent room without disturbing the subject's sleep. To prevent clotting, approximately 700 mL of saline solution were infused during the experimental period. Blood samples were always processed immediately after sampling. Potential side effects of spironolactone were evaluated in the morning by questionnaires. Standard polysomnographic recordings were obtained to assure normal nocturnal sleep. Blood pressure was assessed 30 min after awakening in the morning. Both conditions for a subject were separated by 2 weeks to assure clearance of the drug, and the order of conditions was balanced across subjects. To study changes in relative quantity of CD184 (CXCR4) and CD62L (L-selectin) on the cell subsets, the median fluorescence intensity (MFI) of the labeled anti-CD184-antibody and anti-CD62L-antibody was analyzed.
T cell subpopulations
Hormone assays and sleep analyses
Samples for measuring hormone concentrations were kept frozen at À70°C until assay. Cortisol in serum and adrenocorticotropic hormone (ACTH) in plasma were measured using a commercial assay (Immulite, Siemens Healthcare Diagnostics, Deerfiled, USA). Aldosterone was measured in serum, also using a commercial assay (DPC-Biermann, Bad Nauheim, Germany). Epinephrine and norepinephrine were measured in plasma by standard high-performance liquid chromatography. Sensitivity, intraassay and interassay coefficients of variation were as follows: cortisol 0.2 lg/dL, less than 10%; ACTH 9 pg/mL, less than 9.5%; aldosterone 11 pg/ mL, less than 16%; epinephrine 2 pg/mL, less than 6.5%; norepinephrine 5 pg/mL, less than 6%.
Sleep stages were determined off-line from polysomnographic recordings following standard criteria (Rechtschaffen and Kales, 1968) . For each night, sleep onset (with reference to lights off at 23:00 h), total sleep time (sum of time spent in sleep stages 1, 2, 3, and 4 and REM sleep), and the time as well as percentage of total sleep time spent in the different sleep stages were calculated. In addition, we determined the time between awakening of subjects around 4:00 h for the second administration of spironolactone or placebo and falling asleep again. SWS was defined by the sum of stage 3 and 4 sleep.
Statistical analyses
Analyses of variance (ANOVA) for repeated measurements were calculated on T cell subpopulations (absolute counts, CXCR4 expression, CD62L expression) and hormones. Factors included were ''Condition'' (spironolactone versus placebo), ''Early/late'' (23:00-3:30 h versus 5:00-9:30 h) and ''Time'' (reflecting the four time points of measurements during the early and late night, respectively). We included the factor ''Early/late'' since we expected the effects of spironolactone only during the early night, when the impact of sleep on T cell migration is evident (see Section 1). Degrees of freedom were corrected according to the Greenhouse-Geisser procedure. In case of ANOVA effects, paired t tests were analyzed at single time points. A p-value <0.05 was considered significant. Data are presented as mean ± SEM. Figs. 1 and 2 ).
Results
Absolute counts of T cell subpopulations
Expression of CXCR4 and CD62L
Spironolactone did not influence the expression of CXCR4 on any subpopulation, nor did it affect the time course of CXCR4 expression. The same was true for the expression of CD62L (data not shown). CXCR4 expression was highest in the naïve and central memory subpopulations of CD4 + and CD8 + T cells, and showed a decline over time during the first night half reaching lowest levels 
Hormones
Plasma cortisol showed the typical circadian variation peaking at the time of awakening (Fig. 3) . Levels of aldosterone and ACTH showed a similar time course, both peaking at 8:00 h. Spironolactone enhanced cortisol levels at 9:30 h compared with the placebo condition (F(1,10) = 7.72, p = 0.020, for Condition Â Early/late interaction; p = 0.026 for post hoc pairwise comparison), whereas ACTH levels were not affected by the MR blocker. This pattern is well in line with previous studies (Dodt et al., 1993; Young et al., 1998) which likewise found that MR antagonists increased cortisol in the absence of changes in ACTH. Increases in aldosterone levels after spironolactone administration did not reach significance (F(3,30) = 3.00, p = 0.073, for Condition Â Early/late Â Time interaction; p = 0.033 and 0.093 for post hoc pairwise comparisons at 3:30 and 6:30 h, respectively). Noradrenaline and adrenaline were not influenced by spironolactone. We also calculated a ratio between aldosterone and cortisol because cortisol has an influence on lymphocyte migration which could compete with that of aldosterone. This aldosterone/cortisol ratio was highest during the first half of the night followed by a continuous decrease that leveled out around 6:30 h. However, the ratio was not influenced by spironolactone (Fig. 3) .
Sleep, blood pressure and side effects
Subjects slept normally in both conditions with a predominance of SWS during the first night half and of REM sleep in the second night half, reflecting a sleep architecture typical for laboratory conditions (total sleep time: 436.9 ± 3.84 min, time in sleep stage 1: 35.9 ± 3.19 min, sleep stage 2: 234.9 ± 8.14 min, SWS: 80.4 ± 5.76 min, REM sleep: 85.7 ± 4.70 min). Time between awakening of subjects around 4:00 h for the second administration of spironolactone or placebo and falling asleep again was on average 16.3 ± 3.2 min (collapsed across conditions). In line with a previous report (Steiger et al., 1993) , spironolactone did not influence any of the sleep parameters measured. There was also no difference in blood pressure between both conditions. Spironolactone produced no side effects and subjects who were all blind to the condition were also not able to correctly indicate whether they received placebo or spironolactone.
Discussion
Following findings that sleep enhances the immune response to vaccination (Lange et al., 2003 (Lange et al., , 2011 , here we asked whether such an effect might partly derive from an aldosterone mediated facilitation in the homing of circulating naïve T cells to lymph nodes. Consistent with this view we found that acute blockade of the MR in sleeping humans after administration of spironolactone, compared with a placebo condition, enhances naïve T-helper cell counts in peripheral blood during the early night. This finding reflecting a diminished extravasation of these T cells is well in line with findings in adrenalectomized rats exhibiting a decrease in Thelper cell numbers in blood after 7 days of aldosterone treatment (Miller et al., 1994) . Also, aldosterone appeared to acutely counteract stress-induced increases in lymphocyte numbers in adrenalectomized rats (Dhabhar et al., 1996) , altogether supporting the view that aldosterone via activating MR basically promotes extravasation of T-helper cells. Whereas the number of total CD4 + T cells and their naïve subpopulation showed a robust increase after spironolactone, similar increases in central memory CD4 + and naïve CD8 + T cells were less consistent. Indeed, a lower sensitivity of CD8 + than CD4 + T cells to mineralocorticoid effects is in keeping with previous findings in rats (Miller et al., 1994) where aldosterone likewise reduced only circulating CD4 + but not CD8 + T cells. Also, the decrease in lymphocyte counts induced by sleep is more pronounced in CD4 + than CD8 + T cells (Born et al., 1997) , and the basal clearance rate of CD4 + T cells from blood into lymph nodes is reported to be twice as high as that of CD8 + T cells (Ottaway and Husband, 1992) . Interestingly, the magnitude and time-course of the spironolactone-induced increase in T-helper cell counts during early sleep was considerably similar to that seen in humans when staying awake the night (Born et al., 1997; Lange et al., 2010) , suggesting that nocturnal blocking of MR mimics the effects of nocturnal wakefulness on T-helper cell numbers. The selective effect of spironolactone on the naïve subset of Thelper cells is in accordance with results from earlier experiments indicating differential sensitivity of cell subpopulations to endocrine signals (Dimitrov et al., 2009) . As CD62L is a most important mediator of T cell homing to lymph nodes, our finding that only CD62L + T cells were influenced by spironolactone well fits the view that sleep-associated aldosterone release mediates a preferential accumulation of naïve T cells in lymph nodes where these cells serve the generation of a primary antigen-specific immune response to infection. Compared with previous studies that revealed highest pulse amplitudes of aldosterone release as well as highest aldosterone plasma levels during sleep (Charloux et al., 1999 (Charloux et al., , 2001 , aldosterone levels in the present study were higher in the morning than during the night. However, our blood sampling rate (1/1.5 h) was too low to cover the pulsatile character of nocturnal aldosterone release. The steep morning increase in aldosterone likely reflects an orthostatic response as our subjects got up at 7:00 h and then remained in an upright position.
Spironolactone and its active metabolites reach highest plasma concentration 2 to 5 h after oral administration (Gardiner et al., 1989; Jankowski et al., 1996) , which explains that the increasing effect of spironolactone on T cell counts did not peak until 3:30 h. Interestingly the effect ceased towards the morning although aldosterone levels were increased at that time. However, this rise in aldosterone was paralleled by the circadian morning rise in cortisol, which is thought to mediate an extravasation and redistribution of lymphocytes to the bone marrow via activation of GR (Dimitrov et al., 2009; Fauci, 1975; Ottaway and Husband, 1992) . This effect of cortisol on T cell migration, which reflects a circadian component and is overall not dependent on sleep, is of much higher magnitude compared to the impact of early sleep on peripheral T cell numbers. Thus, any increasing effect of an MR blockade on cell counts in the morning would be masked by the potent cortisol-induced redistribution of T cells to the bone marrow. Additionally, cortisol has been shown to interfere with the migration of lymphocytes from peripheral blood into lymph nodes (Ottaway and Husband, 1992; Sackstein and Borenstein, 1995) , an effect that is also expected to interfere with an aldosterone-mediated redistribution of T cell to lymph nodes during the morning rise in cortisol. Taken together, our finding that effects of spironolactone faded with increasing cortisol concentrations in the morning, suggests that the regulatory influence of aldosterone on T cell counts emerges only in the presence of low cortisol levels, possibly linked to a reduced activation of GR. Indeed, although both cortisol and aldosterone levels increased during the morning hours, the ratio between aldosterone and cortisol was much higher during the early night, when the effects of spironolactone on T cell counts were apparent. This tempts to speculate that rather than MR activation per se, the balance between MR and GR activation is more crucial for the regulation of T cell migration.
On the other hand, the effect of spironolactone fading in the morning hours can be taken to exclude that MR signaling is involved in the prominent circadian decline in T cell numbers at that time. This decline in T cells was paralleled not only by an increase in cortisol but also in CXCR4 expression, i.e., a pattern in line with the view derived from previous studies that cortisol via activation of GR induces CXCR4 expression which in turn accelerates the migration of T cells, presumably into the bone marrow (Dimitrov et al., 2009; Fauci, 1975; Okutsu et al., 2005) . GR and MR can form heterodimers thereby increasing the functional diversity of these receptors (Liu et al., 1995; Nishi et al., 2004; Trapp et al., 1994) . The fact that spironolactone did neither affect CXCR4 expression nor the decrease in blood T cell counts in the morning shows that this pattern is GR driven, and does not require concomitant activation of MR.
Of note, in the absence of the enzyme 11b-hydroxysteroid dehydrogenase 2 cortisol binds MR with even higher affinity than GR (Krozowski et al., 1999; Rupprecht et al., 1993; Zhang et al., 2005) . Estimates from animal studies indicate that during the circadian nadir of glucocorticoid levels about 50 per cent of MR are occupied by endogenous corticosteroids (Kalman and Spencer, 2002) . Therefore, the increasing effect of spironolactone on naïve T cell counts might basically stem also from a blockade of low cortisol levels acting on the MR. However, in humans, there is evidence for a threefold higher affinity of lymphocytic MR for aldosterone than cortisol (Armanini et al., 1985) , making it unlikely that cortisol substantially contributes to MR mediated T cell trafficking during early nocturnal sleep. Also, an unspecific mediation of the effects via non-lymphocytic MR seems unlikely, as the effect was cell-subset specific, with no impact of spironolactone on CD62L À T cells, and we did not observe any effects on blood pressure or sleep architecture, nor did the subjects report any side effects. Though unlikely, it cannot be fully ruled out that non-MR mediated effects of spironolactone, like a down-regulation of IL-2 production (Sonder et al., 2006) , added to the observed increase in circulating T helper cells. Testing with more specific MR antagonists or agonists might help to resolve this issue in future studies. Indeed, preliminary studies of ours revealed a distinct decrease in circulating naïve T cells following administration of the MR agonist fludrocortisone, overall confirming the major role of MR in regulating T cell extravasation.
We suspected that MR signaling impacts migration of naïve Thelper cell counts through increasing expression of the adhesion molecule CD62L. This was not confirmed as spironolactone did not change CD62L expression on any of the T cell subsets. This does not exclude that MR signaling might increase the affinity of CD62L for its ligand which was not tested here. Migration of T cells to lymph nodes also involves activation of the chemokine receptor CCR7 as well as the integrin LFA-1, changes in the expression or affinity of which represent alternative pathways that can mediate facilitating effects of MR signaling on T cell homing. It has recently been shown that aldosterone increases expression of the LFA-1 ligand ICAM-1 on endothelial cells resulting in an enhanced adhesion of leukocytes to the vessel walls (Caprio et al., 2008; Krug et al., 2007) . However, such effect per se would not sufficiently explain why the effect of MR blockade was specific for the naïve T cell subset, which is known to show only moderate LFA-1 expression in comparison to the other subpopulations . The mechanisms underlying this selectivity, hence, need to be clarified in further studies.
In conclusion, we have shown that the blockade of MR by spironolactone enhances the number of circulating naïve T-helper cells during early sleep, whereas the prominent circadian decrease in T cell counts in the morning remained unaffected, which is in line with the view that this circadian decrease in T cells is solely driven by cortisol-induced GR activation. We propose that MR signaling during early nocturnal sleep, on top of these circadian changes, fine-tunes the redistribution and homing of naïve T helper cells to lymph nodes, thereby eventually supporting the formation of immunological memory.
